ID   QGP-1
AC   CVCL_3143
SY   QGP 1; QGP1
DR   BTO; BTO:0005500
DR   CLO; CLO_0037113
DR   EFO; EFO_0006741
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472832
DR   BioSample; SAMN03472892
DR   BioSample; SAMN10988306
DR   cancercelllines; CVCL_3143
DR   Cell_Model_Passport; SIDM00360
DR   CGH-DB; 9375-4
DR   Cosmic; 736280
DR   Cosmic; 922260
DR   Cosmic; 933517
DR   Cosmic; 1620106
DR   Cosmic; 1879412
DR   Cosmic; 2433551
DR   Cosmic; 2530677
DR   Cosmic-CLP; 1298534
DR   DepMap; ACH-000347
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1298534
DR   GEO; GSM600373
DR   GEO; GSM830112
DR   GEO; GSM827299
DR   GEO; GSM887522
DR   GEO; GSM888604
DR   GEO; GSM1374837
DR   GEO; GSM1670355
DR   IARC_TP53; 30149
DR   JCRB; JCRB0183
DR   LiGeA; CCLE_506
DR   LINCS_LDP; LCL-1754
DR   PharmacoDB; QGP1_1280_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3143
DR   Wikidata; Q54948822
RX   CelloPub=CLPUB00598;
RX   DOI=10.5772/30884;
RX   PubMed=1971195;
RX   PubMed=6205259;
RX   PubMed=7227711;
RX   PubMed=8426738;
RX   PubMed=11169959;
RX   PubMed=20215515;
RX   PubMed=21607521;
RX   PubMed=22460905;
RX   PubMed=22929519;
RX   PubMed=23119007;
RX   PubMed=25485619;
RX   PubMed=25612765;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26087898;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29330294;
RX   PubMed=29444439;
RX   PubMed=29444910;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
RX   PubMed=36180704;
WW   https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/QGP-1.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~3.5 days (PubMed=7227711); 61 hours (PubMed=25984343); 1.6 +- 0.3 days (PubMed=29330294); 40-50 hours (Note=Lot 04152003), ~2 days (Note=Lot 02162009), ~42 hours (Note=Lot 04112012), ~74 hours (Note=Lot 05312016) (JCRB=JCRB0183).
CC   HLA typing: A*24:02,24:02; B*15:11,67:02; C*01:21,12:03; DRB1*13:26,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Gln (c.6497G>A); ClinVar=VCV000230267; Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=21607521; PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leufs*25 (c.293delC); Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=82.5%; East Asian, South=17.02%; South Asian=0.48%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Misspelling: QGP; CGH-DB=9375-4; GEO=GSM600373.
CC   Misspelling: QCP-1; DOI=10.5772/30884.
CC   Derived from site: In situ; Pancreas, islets of Langerhans; UBERON=UBERON_0000006.
CC   Cell type: Pancreatic delta cell; CL=CL_0000173.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200; PubMed=29444910
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 10,12 (Cosmic-CLP; JCRB; PubMed=29444910)
ST   D16S539: 12 (PubMed=25877200)
ST   D18S51: 13
ST   D21S11: 29
ST   D3S1358: 14,17
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 14
ST   FGA: 21,23
ST   Penta D: 13
ST   Penta E: 5,24
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,17,18 (JCRB)
ST   vWA: 14,18 (Cosmic-CLP; PubMed=25877200; PubMed=29444910)
DI   NCIt; C95595; Pancreatic somatostatinoma
DI   ORDO; Orphanet_97283; Somatostatinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   CelloPub=CLPUB00598;
RA   Behrang Y.;
RT   "Establishment and characterization of a new human, highly
RT   differentiated and functionally active tumor model of a pancreatic
RT   neuroendocrine tumor.";
RL   Thesis MD (2020), University of Hamburg, Germany.
//
RX   DOI=10.5772/30884;
RA   Ruckert F., Pilarsky C., Grutzmann R.;
RT   "Establishment of primary cell lines in pancreatic cancer.";
RL   (In) Pancreatic cancer. Molecular mechanism and targets; Srivastava S. (eds.); pp.259-274; InTechOpen; London (2012).
//
RX   PubMed=1971195;
RA   Iguchi H., Hayashi I., Kono A.;
RT   "A somatostatin-secreting cell line established from a human
RT   pancreatic islet cell carcinoma (somatostatinoma): release experiment
RT   and immunohistochemical study.";
RL   Cancer Res. 50:3691-3693(1990).
//
RX   PubMed=6205259; DOI=10.1016/0161-5890(84)90028-2;
RA   Kuroki M., Kuroki M., Ichiki S., Matsuoka Y.;
RT   "Identification and partial characterization of the unglycosylated
RT   peptide of carcinoembryonic antigen synthesized by human tumor cell
RT   lines in the presence of tunicamycin.";
RL   Mol. Immunol. 21:743-746(1984).
//
RX   PubMed=7227711; DOI=10.20772/cancersci1959.71.5_596;
RA   Kaku M., Nishiyama T., Yagawa K., Abe M.;
RT   "Establishment of a carcinoembryonic antigen-producing cell line from
RT   human pancreatic carcinoma.";
RL   Gann 71:596-601(1980).
//
RX   PubMed=8426738;
RA   Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G.,
RA   Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E.,
RA   Maurer J., Maacke H., Deppert W.;
RT   "p53 and K-RAS alterations in pancreatic epithelial cell lesions.";
RL   Oncogene 8:289-298(1993).
//
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21607521; DOI=10.3892/or.1.6.1223;
RA   Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y.,
RA   Shimazoe T., Nawata H., Kono A.;
RT   "Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in
RT   human pancreatic cancer-derived cell-lines with different metastatic
RT   potential.";
RL   Oncol. Rep. 1:1223-1227(1994).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22929519; DOI=10.3791/4218;
RA   Wong C., Vosburgh E., Levine A.J., Cong L., Xu E.Y.;
RT   "Human neuroendocrine tumor cell lines as a three-dimensional model
RT   for the study of human neuroendocrine tumor therapy.";
RL   J. Vis. Exp. 66:e4218.1-e4218.7(2012).
//
RX   PubMed=23119007; DOI=10.1371/journal.pone.0048411;
RA   Li S.-C., Martijn C., Cui T., Essaghir A., Luque R.M., Demoulin J.-B.,
RA   Castano J.P., Oberg K., Giandomenico V.;
RT   "The somatostatin analogue octreotide inhibits growth of small
RT   intestine neuroendocrine tumour cells.";
RL   PLoS ONE 7:E48411-E48411(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25612765; DOI=10.1530/JME-14-0304;
RA   Vandamme T., Peeters M., Dogan F., Pauwels P., Van Assche E.,
RA   Beyens M., Mortier G., Vandeweyer G., de Herder W., Van Camp G.,
RA   Hofland L.J., Op de Beeck K.;
RT   "Whole-exome characterization of pancreatic neuroendocrine tumor cell
RT   lines BON-1 and QGP-1.";
RL   J. Mol. Endocrinol. 54:137-147(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002;
RA   Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M.,
RA   Schroth G., Beutler A.S., Banck M.S.;
RT   "Exome-level comparison of primary well-differentiated neuroendocrine
RT   tumors and their cell lines.";
RL   Cancer Genet. 208:374-381(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163;
RA   Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G.,
RA   Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M.,
RA   Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M.,
RA   Izbicki J.R., Lohse A.W., Schrader J.;
RT   "Establishment of the first well-differentiated human pancreatic
RT   neuroendocrine tumor model.";
RL   Mol. Cancer Res. 16:496-507(2018).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36180704; DOI=10.1007/978-1-0716-2593-4_35;
RA   Zibolka J., Bahr I., Peschke E., Muhlbauer E., Bazwinsky-Wutschke I.;
RT   "Human and rodent cell lines as models of functional
RT   melatonin-responsive pancreatic islet cells.";
RL   Methods Mol. Biol. 2550:329-352(2022).
//